A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults

NCT07679282 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2400

Last updated 2026-08-13

No results posted yet for this study

Summary

Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.

Conditions

  • Obstructive Sleep Apnea (OSA)

Interventions

DEVICE

Positive airway pressure (PAP) therapy

Positive airway pressure delivered via a nasal or face mask while a patient sleeps to keep the airways open.

DEVICE

Sleep dental device

An oral appliance worn during sleep to move the lower jaw forward, which tightens soft tissues and widens the airway to prevent sleep apnea.

DRUG

Atomoxetine-oxybutynin

The combination of two medications (atomoxetine-oxybutynin) can reduce obstructive sleep apnea by increasing upper airway muscle activity.

Sponsors & Collaborators

  • Stanford University

    collaborator OTHER
  • Patient-Centered Outcomes Research Institute

    collaborator OTHER
  • University of Arizona

    collaborator OTHER
  • University of Maryland

    collaborator OTHER
  • University of Miami

    collaborator OTHER
  • Sairam Parthasarathy

    lead OTHER

Principal Investigators

  • Sairam Parthasarathy, MD · University of Arizona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2030-03-01
Completion
2032-05-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07679282 on ClinicalTrials.gov